NCT07057778View on ClinicalTrials.gov

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

July 1, 2027

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

Iguratimod

oral iguratimod at 25mg twice daily for 26 weeks

DRUG

low-dose rituximab

rituximab 100mg once weekly for 6 weeks

Trial Locations (1)

Unknown

Peking University Insititute of Hematology, Beijing

All Listed Sponsors
collaborator

Beijing Hospital

OTHER_GOV

collaborator

Beijing Friendship Hospital

OTHER

collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Beijing Tongren Hospital

OTHER

lead

Peking University People's Hospital

OTHER